Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

e of PROCRIT should be titrated for each patient to achieve and maintain hemoglobin levels between 10 to 12 g/dL. If a patient does not attain hemoglobin levels of 10 to 12 g/dL despite 12 weeks of appropriate PROCRIT therapy, see DOSAGE and ADMINISTRATION in the PROCRIT Prescribing Information.
  • Cancer patients: PROCRIT therapy should not be initiated at hemoglobin levels greater than or equal to 10 g/dL. The dose of PROCRIT should be titrated for each patient to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for blood transfusion. Discontinue if after 8 weeks of therapy there is no response as measured by hemoglobin levels or if transfusions are still required (see recommended Dose Modification section in DOSAGE and ADMINISTRATION of the PROCRIT Prescribing Information).
  • HIV patients: The dose of PROCRIT should be titrated for each patient to achieve and maintain the lowest hemoglobin level sufficient to avoid transfusion and not to exceed the upper safety limit of 12 g/dL.
  • Monitor hemoglobin regularly during therapy, weekly until hemoglobin becomes stable.
  • Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with PROCRIT predominantly in patients with chronic renal failure receiving PROCRIT by subcutaneous administration. PRCA has also been reported in patients receiving ESAs while undergoing treatment for Hepatitis C with interferon and ribavirin. If any patient develops a sudden loss of response to PROCRIT, accompanied by severe anemia and low reticulocyte count, and anti-erythropoietin antibody-associated anemia is suspected, withhold PROCRIT and other erythropoietic proteins. Contact ORTHO BIOTECH (1-888-2ASKOBI or 1-888-227-5624) to perform assays for binding and neutralizing antibodies. If
    '/>"/>

  • SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
    10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
    11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
    (Date:8/18/2014)... (Aug. 18, 2014) -- A new therapy developed ... (USF) Morsani College of Medicine and Columbia University ... complications of interventional cardiovascular disease treatment. , ... the novel molecular therapy could selectively inhibit blood ... a medical procedure using a balloon catheter to ...
    (Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
    (Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
    Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
    ... ROCKVILLE, Md., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ... financial,results in a press release to be issued after ... will hold an investor conference call to,discuss its financial ... The call will be hosted by Novavax President and ...
    ... Lead Cancer Stem Cell Product Candidate Enters Clinical ... OncoMed Pharmaceuticals, a,clinical-stage company developing novel antibody therapeutics ... completion of the final,tranche of its Series B ... total Series B financing to $154 million. New ...
    ... at Berlin conference, RALEIGH, N.C., Nov. 4 ... it will present during the,Partnerships in Clinical Trials ... PRA,s Christian Tucat, Senior Vice President of Business,Development ... evolution of CRO,partnerships?" at 4PM on Wednesday, 5 ...
    Cached Biology Technology:Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2OncoMed Pharmaceuticals Completes Series B Financing 2OncoMed Pharmaceuticals Completes Series B Financing 3PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress 2
    (Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
    (Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
    (Date:8/20/2014)... ROBERTS, Washington , August 20, 2014 ... Security Concerns in the Payment Industry?   ... sectors including biometrics, issues commentary from analysts and experts on ... , Managing Partner at Thrive Analytics, Isabelle Moeller ... of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric ...
    Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
    ... Vision Australia (BVA) today unveils their wide-view neurostimulator concept ... Australia,s first recipient of the technology. The ... University of New South Wales and unveiled today at ... Melbourne, will deliver improved quality of life for patients ...
    ... helping fight a multi-front war on cancer may do the ... Cancer and cardiovascular disease, both among top U.S. killers, ... as a treatment could become additional common ground, said Dr. ... think hsp90 inhibitors may be some of the best anti-inflammatory ...
    ... March 30, 2010 Two new tuberculosis studies by ... bad news about the bacterium that infects nearly a ... kills nearly 2 million people each year. ... shows promise at overcoming some drug-resistant tuberculosis, at least ...
    Cached Biology News:Bionic Vision Australia puts bionic eye in sight 2New cancer therapy may fight cardiovascular disease 2UT Southwestern researchers find clues to TB drug resistance 2UT Southwestern researchers find clues to TB drug resistance 3
    ... Our fastest automated perfusion system. ... in perfusion, physiology, biophysics, electrochemistry, or ... reproducibility with 1.5-4 millisecond accuracy ... Microprocessor-based for accuracy and flexibility ...
    Recombinant Human PTP1B (aa 2-321), CF...
    ... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
    FGF Receptor 1 Antibody...
    Biology Products: